Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LX 2006

Next Previous
Drug Profile

LX 2006

Alternative Names: AAVrh.10hFXN; LX-2006

Latest Information Update: 15 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weill Cornell Medicine
  • Developer LEXEO Therapeutics
  • Class Cardiovascular therapies; Gene therapies
  • Mechanism of Action Frataxin expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cardiomyopathies

Most Recent Events

  • 07 Jul 2025 LX 2006 receives Breakthrough Therapy status for Friedreich's ataxia in USA
  • 12 May 2025 LEXEO Therapeutics plans to begin enrollment in a prospective natural history CLARITY-FA study in Q2 2025
  • 12 May 2025 LEXEO Therapeutics plans to initiate registrational trial for Cardiomyopathies by early 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top